medigraphic.com
SPANISH

Revista Mexicana de Urología

Organo Oficial de la Sociedad Mexicana de Urología
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2005, Number 6

<< Back Next >>

Rev Mex Urol 2005; 65 (6)

Morbidity associated with transrectal ultrasound guided biopsy of the prostate with preparation of extended release ciprofloxacin

Martínez MR, Esteban MJ, Calderón G, Gómez GL, Lozano SJF, Cortés GJR
Full text How to cite this article

Language: Spanish
References: 6
Page: 407-411
PDF size: 47.25 Kb.


Key words:

Prostate, biopsy, ultrasonography.

ABSTRACT

Background. Transrectal ultrasound guided biopsy of the prostate (TRUS biopsy) has been made for many years. The biopsy is a safe procedure but not free of complications. Material and methods. We made a TRUS biopsy in 50 patients after preparation including an enema and three doses of extended release ciprofloxacin administered during three consecutive days. We evaluated the presence of rectal bleeding, hematuria or hematospermia and febrile episodes. Results. Hematuria, rectal bleeding and hematospermia were noted in 36, 64 and 24% of the patients biopsed respectively. In many cases the bleeding was self-limiting. There were no febrile episodes in any patient. The morbidity associated with the biopsy did not require any additional treatment or medical visit. Conclusions. The TRUS biopsy of the prostate is a safe procedure. The preparation with a dose of 1 gram of extended release ciprofloxacin per day for a total of three doses is efficient and easy to take. The infectious and/or hemorrhagic complications are rare and without significance when you use this preparation before the biopsy.


REFERENCES

  1. Manikandan R, Srirangam SJ, Brown SCW, et al. Nitrous oxide vs. periprostatic nerve block with 1% lidocaine during transrectal ultrasound guided biopsy of the prostate: A prospective, randomized, controlled trial. J Urol 2003; 170: 1881-3.

  2. Peyromaure M, Ravery V, Messas A, et al. Pain and morbidity of an extensive prostate 10-biopsy protocol: a prospective study in 289 patients. J Urol 2002; 167(1): 218-21.

  3. Paul R, Sholer S, Van Randenborgh H, et al. Morbidity of prostatic biopsy for different biopsy strategies: is there a relation to core number and sampling region? Eur Urol 2004; 45(4): 450-5.

  4. Enlund AL, Varenhorst E. Morbidity of ultrasound guided transrectal core biopsy of the prostate without prophylactic therapy: a prospective study in 415 patients. Br J Urol 1997; 79: 777.

  5. Berger AP, Gozzi Ch, Steiner H, et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 2004; 171: 1478-81.

  6. Lee-Elliot C, Dundas D, Patel U. Randomized trial of lidocaine vs. lidocaine/bupivacaine periprostatic injection on longitudinal pain scores after prostate biopsy. J Urol 2004; 171: 247-50.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Mex Urol. 2005;65